Skip to main content

Table 3 Quality-adjusted survival (QAS) estimated from a sample through the standard gamble (SG) method

From: Cost-utility analysis of adjuvant goserelin (Zoladex) and adjuvant chemotherapy in premenopausal women with breast cancer

  Goserelin Chemotherapy
Life expectancy of patient population 432 ± 23 401 ± 17
Life expectancy of reference population 474 ± 1 467 ± 1
SG of patient population 0.81 0.78
SG of reference population 1 1
QAS of patient population 341 ± 31 336 ± 39
QAS of reference population 476 ± 1 468 ± 1
QAS lost 135 132